Uniplan Investment Counsel Inc. Takes $2.51 Million Position in AxoGen, Inc. $AXGN

Key Points

• Uniplan Investment Counsel Inc. has acquired a new stake in AxoGen, Inc., purchasing 135,479 shares valued at approximately $2.5 million, representing about 0.30% ownership of the company.
• Analysts have mixed reviews on AxoGen, with Canaccord Genuity Group reducing its price target from $26.00 to $24.00, while Wall Street Zen upgraded the stock from "hold" to "buy."
• AxoGen's stock has shown volatility, with a 1-year low of $9.22 and a high of $21.00, currently trading at around $15.98.

Uniplan Investment Counsel Inc. bought a new position in shares of AxoGen, Inc. (NASDAQ:AXGN - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 135,479 shares of the medical equipment provider's stock, valued at approximately $2,506,000. Uniplan Investment Counsel Inc. owned about 0.30% of AxoGen at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Parkman Healthcare Partners LLC boosted its holdings in AxoGen by 46.8% during the first quarter. Parkman Healthcare Partners LLC now owns 536,832 shares of the medical equipment provider's stock worth $9,931,000 after buying an additional 171,129 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in AxoGen by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,185 shares of the medical equipment provider's stock worth $466,000 after buying an additional 1,057 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in AxoGen by 148.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 203,901 shares of the medical equipment provider's stock worth $3,772,000 after buying an additional 121,901 shares during the last quarter. AQR Capital Management LLC boosted its holdings in AxoGen by 45.3% during the first quarter. AQR Capital Management LLC now owns 23,917 shares of the medical equipment provider's stock worth $442,000 after buying an additional 7,453 shares during the last quarter. Finally, Cubist Systematic Strategies LLC boosted its holdings in AxoGen by 166.6% during the first quarter. Cubist Systematic Strategies LLC now owns 112,436 shares of the medical equipment provider's stock worth $2,080,000 after buying an additional 70,268 shares during the last quarter. Institutional investors own 80.29% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded AxoGen from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $26.00.

AxoGen Stock Down 1.8%

NASDAQ AXGN traded down $0.31 during trading on Friday, hitting $16.49. The stock had a trading volume of 319,813 shares, compared to its average volume of 829,505. AxoGen, Inc. has a 12 month low of $9.22 and a 12 month high of $21.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 2.67 and a current ratio of 4.14. The company's 50-day moving average price is $14.01 and its two-hundred day moving average price is $14.29. The company has a market capitalization of $758.75 million, a PE ratio of -165.03 and a beta of 1.03.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.